FDA Approves Acalabrutinib for CLL and SLL
Nov 21
2019
The Food and Drug Administration approved acalabrutinib (CALQUENCE, AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).